|
|
|
|
|
|
Sponsored by: |
Amgen |
Information provided by: | Amgen |
ClinicalTrials.gov Identifier: | NCT00093977 |
The purpose of this study is to determine whether darbepoetin alfa manufactured by the current "roller bottle" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.
Condition | Intervention | Phase |
Kidney Disease Chronic Kidney Disease |
Drug: darbepoetin alfa SF |
Phase III |
ChemIDplus related topics: | Erythropoietin Darbepoetin alfa |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety Study |
Official Title: | An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects With Chronic Kidney Disease |
Estimated Enrollment: | 1100 |
Study Start Date: | October 2004 |
Study Completion Date: | January 2007 |
Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
darbepoetin alfa SF: Experimental |
Drug: darbepoetin alfa SF
Frequency of dosing depends on frequency at randomization: rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Show 121 Study Locations |
Amgen |
Study Director: | MD | Amgen |
AmgenTrials clinical trials website 
  |
Notice regarding posted summaries of trial results 
  |
To access clinical trial results information click on this link 
  |
Responsible Party: | Amgen Inc. ( Global Development Leader ) |
Study ID Numbers: | 20040180 |
First Received: | October 7, 2004 |
Last Updated: | October 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00093977 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|